Fulcrum Therapeutics (FULC) Competitors

Fulcrum Therapeutics logo
$3.74 +0.02 (+0.40%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

FULC vs. MLTX, CVAC, JBIO, SVRA, and ODTX

Should you buy Fulcrum Therapeutics stock or one of its competitors? Fulcrum Therapeutics's main competitors and comparable companies include MoonLake Immunotherapeutics (MLTX), CureVac (CVAC), Jade Biosciences (JBIO), Savara (SVRA), and Odyssey Therapeutics (ODTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fulcrum Therapeutics compare to MoonLake Immunotherapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Fulcrum Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

In the previous week, Fulcrum Therapeutics had 2 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 4 mentions for MoonLake Immunotherapeutics. Fulcrum Therapeutics' average media sentiment score of 0.18 beat MoonLake Immunotherapeutics' score of -0.14 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fulcrum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
MoonLake Immunotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fulcrum Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 120.43%. MoonLake Immunotherapeutics has a consensus target price of $31.33, indicating a potential upside of 190.39%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Fulcrum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulcrum Therapeutics
4 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75
MoonLake Immunotherapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.60

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulcrum TherapeuticsN/AN/A-$74.88M-$1.04N/A
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.67N/A

Fulcrum Therapeutics' return on equity of -19.94% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fulcrum TherapeuticsN/A -19.94% -19.16%
MoonLake Immunotherapeutics N/A -79.95%-56.40%

Summary

Fulcrum Therapeutics beats MoonLake Immunotherapeutics on 7 of the 12 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

CureVac has higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$70.74M14.78$175.50M$0.726.47
Fulcrum TherapeuticsN/AN/A-$74.88M-$1.04N/A

CureVac has a net margin of 199.92% compared to Fulcrum Therapeutics' net margin of 0.00%. Fulcrum Therapeutics' return on equity of -19.94% beat CureVac's return on equity.

Company Net Margins Return on Equity Return on Assets
CureVac199.92% -23.03% -19.09%
Fulcrum Therapeutics N/A -19.94%-19.16%

17.3% of CureVac shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Fulcrum Therapeutics had 6 more articles in the media than CureVac. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 0 mentions for CureVac. Fulcrum Therapeutics' average media sentiment score of 0.18 beat CureVac's score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
CureVac Neutral
Fulcrum Therapeutics Neutral

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the broader market.

Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 120.43%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Fulcrum Therapeutics
4 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75

Summary

Fulcrum Therapeutics beats CureVac on 9 of the 15 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Jade Biosciences had 19 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 25 mentions for Jade Biosciences and 6 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.18 beat Jade Biosciences' score of -0.08 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
3 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fulcrum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Jade Biosciences is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jade BiosciencesN/AN/A-$127.41M-$1.86N/A
Fulcrum TherapeuticsN/AN/A-$74.88M-$1.04N/A

89.8% of Fulcrum Therapeutics shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Jade Biosciences presently has a consensus target price of $51.00, suggesting a potential upside of 229.24%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 120.43%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Jade Biosciences is more favorable than Fulcrum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Fulcrum Therapeutics
4 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75

Jade Biosciences has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.82, meaning that its stock price is 182% more volatile than the broader market.

Fulcrum Therapeutics' return on equity of -19.94% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jade BiosciencesN/A -42.80% -40.09%
Fulcrum Therapeutics N/A -19.94%-19.16%

Summary

Fulcrum Therapeutics beats Jade Biosciences on 7 of the 13 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Savara?

Fulcrum Therapeutics (NASDAQ:FULC) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Fulcrum Therapeutics presently has a consensus price target of $8.20, indicating a potential upside of 120.43%. Savara has a consensus price target of $10.29, indicating a potential upside of 117.92%. Given Fulcrum Therapeutics' higher probable upside, research analysts plainly believe Fulcrum Therapeutics is more favorable than Savara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulcrum Therapeutics
4 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75
Savara
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Fulcrum Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the broader market. Comparatively, Savara has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Savara is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulcrum TherapeuticsN/AN/A-$74.88M-$1.04N/A
SavaraN/AN/A-$118.84M-$0.61N/A

Fulcrum Therapeutics' return on equity of -19.94% beat Savara's return on equity.

Company Net Margins Return on Equity Return on Assets
Fulcrum TherapeuticsN/A -19.94% -19.16%
Savara N/A -96.87%-74.22%

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Savara had 9 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 15 mentions for Savara and 6 mentions for Fulcrum Therapeutics. Savara's average media sentiment score of 1.12 beat Fulcrum Therapeutics' score of 0.18 indicating that Savara is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fulcrum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Savara
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Fulcrum Therapeutics beats Savara on 8 of the 13 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Odyssey Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

In the previous week, Fulcrum Therapeutics had 6 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 0 mentions for Odyssey Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.18 beat Odyssey Therapeutics' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Fulcrum Therapeutics Neutral
Odyssey Therapeutics Neutral

Odyssey Therapeutics' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fulcrum TherapeuticsN/A -19.94% -19.16%
Odyssey Therapeutics N/A N/A N/A

Fulcrum Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 120.43%. Odyssey Therapeutics has a consensus target price of $34.67, indicating a potential upside of 82.65%. Given Fulcrum Therapeutics' higher probable upside, research analysts plainly believe Fulcrum Therapeutics is more favorable than Odyssey Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulcrum Therapeutics
4 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75
Odyssey Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulcrum TherapeuticsN/AN/A-$74.88M-$1.04N/A
Odyssey TherapeuticsN/AN/AN/A-$9.13N/A

Summary

Fulcrum Therapeutics beats Odyssey Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FULC vs. The Competition

MetricFulcrum TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$284.52M$3.95B$7.50B$11.74B
Dividend YieldN/A3.63%2.47%4.65%
P/E Ratio-3.5823.8233.0329.92
Price / SalesN/A15.578.115.47
Price / CashN/A22.7220.8521.62
Price / Book0.954.194.423.71
Net Income-$74.88M-$24.02M$3.51B$394.40M
7 Day Performance1.49%-6.32%-5.15%-5.09%
1 Month Performance0.95%-8.20%-6.09%-7.58%
1 Year Performance-67.55%-4.50%-1.10%-7.23%

Fulcrum Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FULC
Fulcrum Therapeutics
2.15 of 5 stars
$3.74
+0.4%
$8.20
+119.5%
-61.8%$284.52MN/AN/A55
MLTX
MoonLake Immunotherapeutics
3.4195 of 5 stars
$12.56
-0.5%
$31.09
+147.5%
-19.5%$1.07BN/AN/A130
CVAC
CureVac
N/A$4.66
flat
N/AN/A$1.05B$70.74M6.47880
JBIO
Jade Biosciences
2.3203 of 5 stars
$16.40
+5.1%
$51.75
+215.5%
+22.5%$1.04BN/AN/A55
SVRA
Savara
2.8299 of 5 stars
$4.92
-2.6%
$10.25
+108.3%
+13.2%$1.01BN/AN/A70

Related Companies and Tools


This page (NASDAQ:FULC) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners